Lilly touts Ph3 data for once-weekly Type II diabetes medication

Eli Lilly (NYSE:LLY) touted data today from a Phase IIIb study of its once-weekly, injectable Type II diabetes medication, Trulicity.

The insulin-maker reported that its GLP-1 receptor agonist significantly improved blood sugar control in people with Type II diabetes when added to ongoing treatment with a SGLT-2 inhibitor.

Get the full story at our sister site, Drug Delivery Business News.

The post Lilly touts Ph3 data for once-weekly Type II diabetes medication appeared first on MassDevice.

from MassDevice http://ift.tt/2CKqexM